Quest Diagnostics Prices $500 Million of Senior Notes
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) priced a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036 under its shelf registration. The company expects net proceeds at closing on May 6, 2026, to be used for general corporate purposes, which may include repaying indebtedness.
The announcement notes the company may repay its $500 million aggregate principal amount of 3.45% senior notes maturing on June 1, 2026. The offering will be made via a prospectus supplement and base prospectus; bookrunners include Goldman Sachs, J.P. Morgan, and Mizuho.
Positive
- Raises $500 million in long-term financing maturing 2036
- Proceeds available for repayment of near-term maturing debt
- Maintains corporate liquidity and financing flexibility
Negative
- New notes carry a 5.000% coupon versus 3.45% on maturing notes
- Higher interest cost on refinanced debt could increase financing expense
News Market Reaction – DGX
In the Apr 28 session, DGX declined 0.80%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | Earnings results | Positive | +4.5% | Strong Q1 2026 results and raised full‑year revenue and EPS guidance. |
| Apr 16 | Research collaboration | Positive | +0.0% | Multi‑year MRD ctDNA collaboration with City of Hope across multiple cancers. |
| Mar 19 | Earnings date notice | Neutral | -0.6% | Announcement of Q1 2026 earnings release date and conference call details. |
| Mar 12 | Board change | Positive | -0.6% | Election of former large‑cap healthcare CEO Timothy Wentworth to board. |
| Mar 02 | Product launch | Positive | -0.8% | Launch of Quest AI Companion in MyQuest using Google’s Gemini models. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Strong earnings with raised guidance saw a clear positive reaction, while strategic and product announcements have recently produced muted or slightly negative moves.
Over recent months, Quest Diagnostics reported solid Q1 2026 results with raised full‑year revenue and EPS guidance, which was followed by a 4.45% gain. Earlier, the company announced a multi‑year MRD research collaboration, an AI lab‑results companion, an earnings date notice, and a new board member, with share moves ranging from slightly negative to flat. Against this backdrop of growth investments and innovation, the new senior notes pricing fits a pattern of active capital and balance‑sheet management.
Key Terms
senior notes financial
shelf registration statement regulatory
prospectus supplement regulatory
base prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Quest Diagnostics expects to receive the net offering proceeds upon closing on May 6, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay with the net proceeds of this offering includes its
This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. This offering may be made only by means of a prospectus supplement and accompanying base prospectus, copies of which or information concerning this offering may be obtained by calling Goldman Sachs & Co. LLC, toll free at 1 (866) 471-2526, J.P. Morgan Securities LLC, collect at 1-212-834-4533 or Mizuho Securities
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in
Forward Looking Statements
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs, including with regard to the consummation of the offering of the Notes, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-prices-500-million-of-senior-notes-302754723.html
SOURCE Quest Diagnostics